Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1Liposarcoma 1

Interventions

Temozolomide 16Irinotecan 13Cyclophosphamide 11dinutuximab 9naxitamab 7Vincristine 7Carboplatin 6sargramostim 5Melphalan 5Granulocyte-Macrophage Colony-Stimulating Factor 5Etoposide 5fludarabine 4Topotecan 4Thiotepa 4Eflornithine 4Doxorubicin 4Cisplatin 4etoposide phosphate 3Zoledronic Acid 3Specimen Handling 3Isotretinoin 3Granulocyte Colony-Stimulating Factor 3saponin QA-21V1 2lutetium Lu 177 dotatate 2aldesleukin 2Vorinostat 2Stem Cell Transplantation 2Radiation 2Platinum 2Mesna 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neuroblastoma × silmitasertib × Clear all
NCT06541262 2026-04-09

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
104 enrolled
CNSSarcoma

Liposarcoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡